Laura Hogan

Division Chief, Pediatric Hematology/Oncology, Stony Brook University Cancer Center, Answers the Most Common Questions from Parents About Childhood Cancer. · Stony Brook Medicine

Credentials: · · ·

History

Pediatric Hematology/Oncology Division · Stony Brook Medicine
Present
Pediatric Hematology/Oncology, Stony Brook Cancer Center Division · Stony Brook Medicine
Present
Division Chief · Stony Brook Medicine
Present

Pediatric Hematology-Oncology
2007–2008
Pediatrics
2004–2007
Doctor of Medicine
2000–2004

Research

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell…
JAMA · 2021 · 318 citations
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia
Nature Genetics · 2013 · 230 citations
Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies
Blood · 2011 · First of 14 authors · 167 citations

Elizabeth Raetz
9 papers
Teena Bhatla
8 papers · 1 as a fellow
William Carroll
7 papers
Stephen Hunger
6 papers
Deepa Bhojwani
4 papers
Mignon Loh
4 papers
David Teachey
3 papers
Lia Gore
3 papers
Christine Cahaney
2 papers · 2 as a resident
ES
Elad Sharon
2 papers
GC
Gregory Condos
2 papers
JP
Joanna Pierro
2 papers

Clinical trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031